Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2022-12-12 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
[기재정정]타법인주식및출자증권취득결정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean DART system titled '타법인주식및출자증권취득결정' (Decision to acquire shares and equity securities of another corporation). It details a specific corporate action regarding an investment in another company (PCL) and includes a correction notice (정정신고). This type of filing is a standard regulatory disclosure regarding corporate investment activities, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies a takeover or merger) or capital changes (which usually implies issuing own shares).
2022-12-12 Korean
[기재정정]타법인주식및출자증권처분결정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean DART system regarding a 'Decision on Disposal of Shares and Securities of Other Corporations' (타법인주식및출자증권처분결정). It details a correction (정정신고) to a previous filing concerning the method of payment for a third-party capital increase (changing from in-kind contribution to cash payment). Since this is a specific regulatory announcement regarding corporate transactions and capital structure adjustments that does not fit into the other specialized categories like M&A or Share Issues, it is classified as a Regulatory Filing (RNS).
2022-12-12 Korean
신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure regarding a 'New Facility Investment' (신규시설투자) by the company Olix. It details the investment amount, purpose (R&D center construction), and board approval date. Since this is a specific corporate announcement regarding capital expenditure and facility investment that does not fit into the other specialized categories like M&A or share issues, it is classified as a general regulatory filing.
2022-11-25 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 95% confidence The document is a formal regulatory filing from the company 'OliX' regarding the 'Decision to Acquire Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). This is a standard corporate disclosure in the Korean market (DART system) detailing the acquisition of shares in 'PCL', including the number of shares, acquisition amount, purpose, and financial status of the target company. Since this is a specific corporate action announcement regarding an investment/acquisition, it falls under the 'Regulatory Filings' category as it is a mandatory disclosure of a material corporate event.
2022-11-11 Korean
타법인주식및출자증권처분결정
M&A Activity Classification · 95% confidence The document is a formal regulatory filing from a Korean company (OliX) regarding the 'Decision to Dispose of Shares and Equity Securities of Another Corporation' (타법인주식및출자증권처분결정). This is a specific type of corporate disclosure required by the Korea Exchange (KRX) for material events. Since it details the disposal of assets/shares in a subsidiary, it falls under the category of general regulatory announcements/filings as it does not fit into specific categories like M&A (which usually implies a takeover or merger) or Share Issue (which is for the company's own shares). Therefore, it is classified as a Regulatory Filing (RNS).
2022-11-11 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Olix Inc. (올릭스 주식회사) covering the period from January 1, 2022, to September 30, 2022. It contains detailed business descriptions, financial data, and management information. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year (quarterly) that contains actual financial statements or substantive financial data is classified as an Interim / Quarterly Report (IR). 9M 2022
2022-11-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.